Source comparison
PT-141 Intranasal Research: Delivery Mechanism Comparison
Intranasal 80–85% 45–60 minutes ~2.7 hours Bypassed entirely Clinical trials, FDA-approved formulation (Vyleesi), rapid-onset studies Subcutaneous 40–60% 90–120 minutes ~2.3 hours 40–60% degradation Early preclinical models, dose-escalation studies Intravenous
This comparison does not assign a generated winner or score.
- Intranasal
- 80–85%
- 45–60 minutes
- ~2.7 hours
- Bypassed entirely
- Clinical trials, FDA-approved formulation (Vyleesi), rapid-onset studies
- Subcutaneous
- 40–60%
- 90–120 minutes
- ~2.3 hours
- 40–60% degradation
- Early preclinical models, dose-escalation studies
- Intravenous
- ~95%
- 5–10 minutes
- ~2.1 hours
- Pharmacokinetic studies only. Not practical for behavioural research
- Oral
- <5% (non-viable)
- N/A
- Complete degradation
- Not used. Peptide bonds hydrolyse in gastric acid
- Professional Assessment
- Intranasal delivery is the gold standard for PT-141 research in 2026. It combines high bioavailability, predictable Tmax, and eliminates injection-site variables. Subcutaneous routes persist in legacy protocols but offer no pharmacokinetic advantage. IV administration is reserved for single-dose PK characterisation and provides no benefit for multi-dose behavioural studies.